Ronald Witteles, MD, FACC

Ronald Witteles, MD, FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Alnylam(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Pfizer Inc(SIGNIFICANT), BridgeBio(SIGNIFICANT), Alexion(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT)

View Full Disclosure